CEO Letter To Shareholders January 6, 2015: Dear Shareholders, 2014 was a year of transition for Immune Pharmaceuticals. We obtained a NASDAQ listing, raised
over $20 million in equity, reduced past liabilities and strengthened our cash position.
27th Annual ROTH Conference
The Ritz-Carlton in Dana Point, CA
Presentation Date: March 11, 2015
Presentation Time: 12:30 PM
Presentation Room: Track 4: The Colonnade
Register for webcast at:
See More Events
IMMUNE is focused on developing the next generation of monoclonal antibodies to
address significant unmet medical needs in
the treatment of cancer and inflammatory diseases. Our goal is to improve patients’ lives through targeted medicine.